Clinical Trials Logo

Myasthenia Gravis Crisis clinical trials

View clinical trials related to Myasthenia Gravis Crisis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05214612 Recruiting - Clinical trials for Nervous System Diseases

Predictors and Prognostic Factors of Myasthenia Gravis Outcome

Start date: January 1, 2022
Phase:
Study type: Observational

This study aims to characterize the clinical features, frequency of different subgroups of MG, and identify predictors of treatment responsiveness among different subgroups of MG. The predictors are including primary outcome (percentage of changes in MG scales at baseline at time of enrollment and after 3 months) and secondary outcome (treatment-related adverse events). Also it aims to determine the frequency of patients with refractory MG. This information will be used to understand the trends and mechanisms of disease relapse, and optimal management strategies.

NCT ID: NCT04674605 Recruiting - Myasthenia Gravis Clinical Trials

A Prospective Cohort Study Of Myasthenia Gravis

Start date: December 31, 2020
Phase:
Study type: Observational [Patient Registry]

The average annual incidence of Myasthenia gravis is up to (8.0-20.0) / 100,000 people. Myasthenia gravis is an acquired autoimmune disease. All skeletal muscles of patients may be involved. When ocular muscles are involved, ptosis, diplopia and other symptoms may occur. When the laryngopharyngeal muscles are involved, the patient may develop dysarthria, dysphagia and other symptoms. However, when the respiratory muscles are involved, patients will have difficulty in breathing, and some patients may develope myasthenia crisis, and artificial assisted respiratory therapy is often needed. This study is a prospective observational study, in which patients are continuously enrolled, basic information of patients is collected, and biological samples are collected. The purpose of this study is to improve the diagnosis and prognosis of myasthenia gravis patients.